Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2019.12.20, EP 19218724
Apostolova Petya ET AL: "Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy", New England Journal of medicine 382:3, 16 January 2020 (2020-01-16), XP055786718, Retrieved from the Internet: URL:https://www.nejm.org/doi/pdf/10.1056/N EJMc1912274?articleTools=true [retrieved on 2021-03-17] (B1)
CHEUNG VINCENT TING FUNG ET AL: "Immunotherapy induced enterocolitis and gastritis - What to do and when?", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, BAILLIERE TINDALL, LONDON, US, vol. 48, 1 October 2020 (2020-10-01), XP086405350, ISSN: 1521-6918, DOI: 10.1016/J.BPG.2020.101703 [retrieved on 2020-10-23] (B1)
JACKSON LEANNE K ET AL: "Oral health in oncology: impact of immunotherapy", SUPPORTIVE CARE IN CANCER, SPRINGER VERLAG, BERLIN, DE, vol. 23, no. 1, 13 September 2014 (2014-09-13), pages 1-3, XP035462786, ISSN: 0941-4355, DOI: 10.1007/S00520-014-2434-6 [retrieved on 2014-09-13] (B1)
WO-A1-99/02215 (B1)
PEREZ-RUIZ ELISABETH ET AL: "Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 569, no. 7756, 1 May 2019 (2019-05-01), pages 428-432, XP036782833, ISSN: 0028-0836, DOI: 10.1038/S41586-019-1162-Y [retrieved on 2019-05-01] (B1)
TRINH SARALINH ET AL: "Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines", ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, vol. 6, no. 2, 1 June 2019 (2019-06-01), page 154, XP055786728, ISSN: 2347-5625, DOI: 10.4103/apjon.apjon_3_19 Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC6371672/pdf/APJON-6-154.pdf> (B1)
NI MING ET AL: "Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis", FRONTIERS IN IMMUNOLOGY, vol. 10, 20 March 2019 (2019-03-20), page 547, XP055786722, DOI: 10.3389/fimmu.2019.00547 Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC6436423/pdf/fimmu-10-00547.pdf> (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP4077639)
|
Utgående
EP Registreringsbrev (3210) (PTEP4077639)
|
Innkommende, AR627075887
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 5. avg. år (EP) | 2024.12.27 | 2150 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |
32410069 expand_more expand_less | 2024.09.02 | 7150 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
7150 = 1 X 7150
|